Key result
Biomarker-guided therapies lack randomized trial evidence of benefit for hard cardiovascular outcomes.
Why the study?
Contemporary biomarkers including lipoprotein(a), coronary artery calcium scoring, and high-sensitivity C-reactive protein are increasingly used to refine risk and guide therapy, yet randomized trials showing that biomarker-guided or biomarker-targeted treatment improves hard clinical endpoints are lacking despite favorable guideline recommendations.
Does biomarker-guided or biomarker-targeted therapy improve hard clinical endpoints (cardiovascular events and mortality) in preventive cardiology?
Does biomarker-guided or biomarker-targeted therapy improve hard clinical endpoints (cardiovascular events and mortality) in preventive cardiology?
This review argues that clinical practice recommendations for emerging biomarker-guided therapies should await randomized trials adequately powered to demonstrate improvements in hard cardiovascular events and mortality.
Answers are grounded in this paper and cite their sources.
Supports deferring emerging biomarker-guided therapies until event-driven RCTs report; leaves open validation of Lp(a), CAC, or hs-CRP targets.
In preventive cardiology, low-density lipoprotein cholesterol and blood pressure are validated surrogate endpoints, with multiple randomized trials demonstrating that their reduction improves cardiovascular morbidity and mortality. In contrast, raising high-density lipoprotein cholesterol (HDL-C) with niacin or cholesteryl ester transfer protein inhibitors failed to improve outcomes despite promising observational data and biological plausibility. In the Cardiac Arrhythmia Suppression Trial of class IC antiarrhythmics to suppress premature ventricular complexes, biomarker-targeted therapy increased mortality. Contemporary biomarkers, including lipoprotein(a), coronary artery calcium scoring, and high-sensitivity C-reactive protein, are increasingly used to refine risk and guide therapy. However, despite favorable guideline recommendations, randomized trials showing that biomarker-guided or biomarker-targeted treatment improves hard clinical endpoints are lacking. This review presents historical biomarker reversals in cardiology and critically appraises the evidence supporting emerging biomarkers. Our core argument is that practice recommendations for biomarker-guided therapy should await appropriately designed randomized trials adequately powered for cardiovascular events and mortality.
No takes yet. Share an insight, caveat, or question.
Shafqat et al. (2026) conducted a review in Cardiovascular disease prevention and risk refinement. Biomarker-guided or biomarker-targeted therapy (e.g., lipoprotein(a), coronary artery calcium scoring, hs-CRP) was evaluated on Hard clinical endpoints (cardiovascular events and mortality). Contemporary biomarker-guided therapies lack randomized trial evidence demonstrating improved hard clinical endpoints, and recommendations should await trials powered for cardiovascular events.
Synapse has enriched 10 related papers. Consider them for comparative context: